Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway

Infection and Immunity

Volumn 66, Issue 10, 1998, Pages 4845-4850

  Zhang, Mason X ^a   Kozel, Thomas R ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; MANNAN;

ALTERNATIVE RNA SPLICING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANDIDA ALBICANS; CELL TYPE; COMPLEMENT ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TIME; PRIORITY JOURNAL; YEAST CELL;

EID: 0031691926     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.10.4845-4850.1998     Document Type: Article

References (40)

1. 2 fragment for activation of the complement system through the alternative pathway. I. disulfide bonds. Mol. Immunol. 18:925-934.
2. Aydintug, M. K., R. W. Leid, and P. R. Widders. 1990. Antibody enhances killing of Tritrichomonas foetus by the alternative bovine complement pathway. Infect. Immun. 58:944-948.
3. Bjornson, A. B., and J. S. Lobel. 1986. Lack of a requirement for the Fc region of IgG in restoring pneumococcal opsonization via the alternative complement pathway in sickle cell disease. J. Infect. Dis. 154:760-769.
4. Calderone, R. A., and P. C. Braun. 1991. Adherence and receptor relationships of Candida albicans. Microbiol. Rev. 55:1-20.
5. Edwards, M. S., A. Nicholson-Weller, C. J. Baker, and D. L. Kasper. 1980. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J. Exp. Med. 151:1275-1287.
6. Ehrnst, A. 1978. Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway. J. Immunol. 121:1206-1212.
7. Eisenberg, R. A., and J. H. Schwab. 1986. Arthropathic group A streptococcal cell walls require specific antibody for activation of human complement by both the classical and alternative pathways. Infect. Immun. 53:324-330.
8. Fraker, P. J., and J. C. Speck, Jr. 1978. Protein and cell membrane iodinations with a sparingly soluble chloroamide, l,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80:849-857.
9. Gelfand, J. A., D. L. Hurley, A. S. Fauci, and M. M. Frank. 1978. Role of complement in host defense against experimental disseminated candidiasis. J. Infect. Dis. 138:9-16.
10. Greenfield, R. A., J. L. Stephens, M. J. Bussey, and J. M. Jones. 1983. Quantitation of antibody to Candida mannan by enzyme-linked immunosorbent assay. J. Lab. Clin. Med. 101:758-771.
11. Hammer, C. H., G. H. Wirtz, L. Renfer, H. D. Gresham, and B. F. Tack. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256:3995-4003.
12. Hoover, D. L., M. Berger, M. H. Oppenheim, W. T. Hockmeyer, and M. S. Meltzer. 1985. Cytotoxicity of human serum for Leishmania donovani amastigotes: antibody facilitation of alternate complement pathway-mediated killing. Infect. Immun. 47:247-252.
13. 2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. J. Immunol. 131:2563-2569.
14. Jones, J. M. 1980. Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect. Immun. 30:78-89.
15. Kanbe, T., M. A. Jutila, and J. E. Cutler. 1992. Evidence that Candida albicans binds via a unique adhesion system on phagocytic cells in the marginal zone of the mouse spleen. Infect. Immun. 60:1972-1978.
16. Kerr, M. A. 1981. Human factor B. J. Pathol. Bacteriol. 80:102-111.
17. Kipnis, T. L., A. U. Krettli, and W. Dias Da Silva. 1985. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand. J. Immunol. 22:217-226.
18. Kobayashi, H., N. Shibata, H. Mitobe, Y. Ohkubo, and S. Suzuki. 1989 Structural study of phosphomannan of yeast-form cells of Candida albicans J-1012 strain with special reference to application of mild acetolysis. Arch. Biochem. Biophys. 272:364-375.
19. Kozel, T. R., R. R. Brown, and G. S. T. Pfrommer. 1987. Activation and binding of C3 by Candida albicans. Infect. Immun. 55:1890-1894.
20. Kozel, T. R., and G. S. T. Pfrommer. 1986. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52:1-5.
21. Kozel, T. R., L. C. Weinhold, and D. M. Lupan. 1996. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. 64:3360-3368.
22. Kozel, T. R., M. A. Wilson, G. S. T. Pfrommer, and A. M. Schlageter. 1989. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57:1922-1127.
23. Lehmann, P. F., and E. Reiss. 1980. Comparison by ELISA of serum anti-Candida albicans mannan IgG levels of a normal population and in diseased patients. Mycopathologia 70:89-93.
24. Lesavre, P. H., T. E. Hugli, A. F. Esser, and H. J. Muller-Eberhard. 1979. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 123:529-534.
25. Lyon, F. L., R. F. Hector, and J. E. Domer. 1986. Innate and acquired immune responses against Candida albicans in congenic B10.D2 mice with deficiency of the C5 complement component. J. Med. Vet. Mycol. 24:359-367.
26. Moore, F. D., Jr., K. F. Austen, and D. T. Fearon. 1982. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J. Immunol. 128:1302-1306.
27. Moore, F. D., Jr., D. T. Fearon, and K. F. Austen. 1981. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J. Immunol. 126:1805-1809.
28. Morelli, R., and L. T. Rosenberg. 1971. Role of complement during experimental Candida infection in mice. Infect. Immun. 3:521-523.
29. Nelson, B., and S. Ruddy. 1979. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J. Immunol. 122:1994-1999.
30. Polhill, R. B., Jr., S. L. Newman, K. M. Pruitt, and R. B. Johnston, Jr. 1978. Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J. Immunol. 121:371-376.
31. Ratnoff, W. D., D. T. Fearon, and K. F. Austen. 1983. The role of antibody in the activation of the alternative complement pathway. Springer Semin. Immunopathol. 6:361-371.
32. Schenkein, H. A., and S. Ruddy. 1981. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for zymosan enhances alternative pathway activation by zymosan. J. Immunol. 126:7-10.
33. Schenkein, H. A., and S. Ruddy. 1981. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J. Immunol. 126:11-15.
34. Schreiber, R. D., M. K. Pangburn, P. H. Lesavre, and H. J. Müller-Eberhard. 1978. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. USA 75:3948-3952.
35. Sim, R. B., and R. G. DiScipio. 1982. Purification and structural studies on the complement-system control protein β1H (factor H). Biochem. J. 205:285-293.
36. Sissons, J. G. P., N. R. Cooper, and M. B. A. Oldstone. 1979. Alternative complement pathway-mediated lysis of measles virus infected cells: induction by IgG antibody bound to individual viral glycoproteins and comparative efficacy of F(ab')2 and Fab' fragments. J. Immunol. 123:2144-2149.
37. Steele, N. P., R. S. Munson, D. M. Granoff, J. E. Cummins, and R. P. Levine. 1984. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect. Immun. 44:452-458.
38. Tack, B. F., J. Janatova, M. L. Thomas, R. A. Harrison, and C. H. Hammer. 1981. The third, fourth, and fifth components of human complement: isolation and biochemical properties. Methods Enzymol. 80:64-101.
39. Wachter, E., and V. Brade. 1989. Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica. Infect. Immun. 57:1984-1989.
40. Zhang, M. X., D. M. Lupan, and T. R. Kozel. 1997. Mannan-specific IgG antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65:3822-3827.